London, United Kingdom, May 20, 2016 --(PR.com
)-- Hosted by Conrad Lichtenstein, Founder and Chief Scientific Officer from Nemesis Bioscience Ltd; and Neil Woodford, Head of the Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit at Public Health England, the interactive training workshop will address key questions surrounding AMR, such as:
· How can funding strategies encourage investment?
· What are the alternative approaches to antimicrobial drug development - peptides, phage therapy, immunotherapy, microbiome engineering?
· How can regulatory initiatives improve new drug development?
· How can epidemiological studies and genome sequencing optimise the use of current antimicrobials?
Previous attendees at SMi's workshops on AMR include:
ABAC Therapeutics, Absynth Biologics, Achaogen, Actelion, Atlas Genetics, BIOASTER, Brandenburg Antiinfektiva GmbH and Forschungszentrum Borstel, Emergent Biosolutions, Evotec, MHRA, Propharma Partners Ltd, Roche, Syner-Med Ltd, TranScrip Partners, Vifor (International) Ltd, Voyage tour.
Details are available at: www.smi-online.co.uk/goto/2016antimicrobial-resistance.asp
Note to Editor: The Superbugs & Superbugs USA Conference will take place on 14th & 15th November in Iselin, New Jersey. Preliminary details are available online at www.superbugs-usa.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk